Elan, Wyeth’s Bapineuzumab Data Mixed In Phase II For AD
This article was originally published in The Pink Sheet Daily
Executive Summary
Antibody works in non-carriers of ApoE4 gene.
You may also be interested in...
Whatever Works – Or Might: Pfizer/Wyeth May Keep Both Alzheimer’s Bets
Sources close to the situation say the merged Pfizer/Wyeth entity will probably maintain ongoing Phase III development programs for both dimebon, the Alzheimer's disease medicine Pfizer in-licensed earlier this year, and bapineuzumab, the antibody being tested by Wyeth and Elan. And the reason has as much to do with the much-bandied "shots on goal" strategy as with efficacy signals exhibited so far by either drug
Whatever Works – Or Might: Pfizer/Wyeth May Keep Both Alzheimer’s Bets
Sources close to the situation say the merged Pfizer/Wyeth entity will probably maintain ongoing Phase III development programs for both dimebon, the Alzheimer's disease medicine Pfizer in-licensed earlier this year, and bapineuzumab, the antibody being tested by Wyeth and Elan. And the reason has as much to do with the much-bandied "shots on goal" strategy as with efficacy signals exhibited so far by either drug
Whatever Works – Or Might: Pfizer/Wyeth Likely To Keep Both Alzheimer’s Bets
Phase III bapineuzumab could be shaky and same-stage dimebon possibly more solid, but victory with either could spell ‘blockbuster.’